ClinicalTrials.gg
CompletedNCT00168038Updated Nov 23, 2011Results posted

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

A Phase 3 interventional study of Immunoglobulin Intravenous (Human) in Immune Thrombocytopenic Purpura, sponsored by CSL Behring. Completed at 17 sites in 6 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-11-23.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland — 8 open to participants now, 10 under way, 6 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Poland.

Enrollment
25th of 38
58 · median 69
Started
2004
the only one that year
Phase 3
22 of 38
4 open now
Registered
4th of 38
by date

Among the 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland, this one is the 25th largest by enrollment, is the only one that started in 2004, is one of 22 in phase 3, and was the 4th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

8 of the 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP). The main efficacy parameter is the proportion of patients responding to treatment by an increase of platelet count to ≥ 50 x 10\^9/L.

03

Conditions studied

  • Immune Thrombocytopenic Purpura

Keywords

  • Chronic Immune Thrombocytopenic Purpura
  • Chronic Idiopathic Thrombocytopenic Purpura
  • Werlhofs Disease
  • Autoimmune Thrombocytopenia
  • Immunglobulin Intravenous
  • Chronic ITP
  • Platelet count
  • Thrombocytopenia
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of chronic ITP defined by: Failure to find other causes of thrombocytopenia; count ≤ 150 x 10\^9/L over 6 months or response to a previous treatment with subsequent decrease in platelet count even if duration of chronic ITP is less than 6 months
  • Platelet counts ≤ 20 x 10\^9/L

Key Exclusion Criteria:

  • Planned splenectomy throughout the study period
  • Treatment with IVIG or anti-D immunoglobulin within 3 weeks prior to screening
  • Treatment with or other immunomodulatory drugs within 3 weeks prior to screening
  • Treatment with intravenous within 10 days prior to screening
  • Change of oral steroid treatment within 15 days prior to screening
  • Patients with known or suspected to immunoglobulins or previous severe side effects to immunoglobulin therapy
  • Abnormal results in the following laboratory parameters: \< 10 g/dL; Total > 1.5 x upper normal limit; ALAT > 2.5 x upper normal limit; ASAT > 2.5 x upper normal limit; Creatinine > 1.5 x upper normal limit; Urea > 1.5 x upper normal limit
  • Positive direct Coombs test
  • Patients with one of the following concomitant diseases Clinical active SLE Known or suspected infection Acute hepatitis Clinically active chronic hepatitis Lymphoproliferative disease Heart failure Grade III or IV according to the classification
  • Any other concomitant disease that has influence on the clotting system (i.e. hemophilia)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    IgPro10

    Biological: Immunoglobulin Intravenous (Human)

Interventions

  • A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.

    Also known as: Privigen, IgPro10

06

What researchers measure

Primary outcomes

  1. Platelet Response

    The platelet response rate is defined as the percentage of subjects responding to treatment with an increase of platelet count from ≤ 20 x 10\^9/L to ≥ 50 x 10\^9/L within the specified time frame.

    Time frame: 7 days

Secondary outcomes

  1. Regression of Hemorrhage (Skin)

    Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

    Time frame: up to 29 days

  2. Regression of Hemorrhage (Oral Cavity)

    Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

    Time frame: 29 days

  3. Regression of Hemorrhage (Genitourinary Tract)

    Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

    Time frame: 29 days

  4. Regression of Hemorrhage (Nose)

    Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

    Time frame: 29 days

  5. Regression of Hemorrhage (Internal)

    Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

    Time frame: 29 days

  6. Time to Platelet Response

    Median time to reach a platelet count ≥ 50 x 10\^9/L.

    Time frame: 29 days

  7. Duration of Platelet Response

    The number of days the platelet count remained ≥ 50 x 10\^9/L.

    Time frame: up to 29 days

  8. Maximum Platelet Level

    Maximum absolute platelet count achieved over the duration of the study.

    Time frame: 29 days

07

Results

Posted Nov 23, 2011

Participant flow

The study was performed as a multicenter study at 17 centers, 6 in Poland, 4 in the Ukraine, 4 in Russia, 1 in Germany, 1 in Italy and 1 in the United Kingdom (UK).

Participant flow — Overall Study
MilestoneIgPro10
Started57
Completed55
Not completed2
Withdrew: Adverse event1
Withdrew: Therapy failure1

Outcome measures

PrimaryPlatelet Response

The platelet response rate is defined as the percentage of subjects responding to treatment with an increase of platelet count from ≤ 20 x 10\^9/L to ≥ 50 x 10\^9/L within the specified time frame.

Time frame:
7 days
Reported as:
Number · Percent of participants
Platelet Response
Percent of participantsIgPro10
Platelet Response80.7 (69.2 to 89.3)
SecondaryRegression of Hemorrhage (Skin)

Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

Time frame:
up to 29 days
Reported as:
Number · participants
Regression of Hemorrhage (Skin)
participantsIgPro10
Regression of Hemorrhage (Skin)31
SecondaryRegression of Hemorrhage (Oral Cavity)

Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

Time frame:
29 days
Reported as:
Number · participants
Regression of Hemorrhage (Oral Cavity)
participantsIgPro10
Regression of Hemorrhage (Oral Cavity)11
SecondaryRegression of Hemorrhage (Genitourinary Tract)

Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

Time frame:
29 days
Reported as:
Number · participants
Regression of Hemorrhage (Genitourinary Tract)
participantsIgPro10
Regression of Hemorrhage (Genitourinary Tract)7
SecondaryRegression of Hemorrhage (Nose)

Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

Time frame:
29 days
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryRegression of Hemorrhage (Internal)

Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.

Time frame:
29 days
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryTime to Platelet Response

Median time to reach a platelet count ≥ 50 x 10\^9/L.

Time frame:
29 days
Reported as:
Median · days
Time to Platelet Response
daysIgPro10
Time to Platelet Response2.5 (1.0 to 5.0)
SecondaryDuration of Platelet Response

The number of days the platelet count remained ≥ 50 x 10\^9/L.

Time frame:
up to 29 days
Reported as:
Median · days
Duration of Platelet Response
daysIgPro10
Duration of Platelet Response15.4 (8.8 to 21.9)
SecondaryMaximum Platelet Level

Maximum absolute platelet count achieved over the duration of the study.

Time frame:
29 days
Reported as:
Median · 10^9/L
Maximum Platelet Level
10^9/LIgPro10
Maximum Platelet Level154 (10 to 1049)

Adverse events

Collected over 28 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro10—3/57 (5.3%)52/57 (91.2%)
Most frequent serious events
Most frequent serious events
EventIgPro10
DizzinessNervous system disorders1/57
Meningitis asepticInfections and infestations1/57
Sudden hearing lossEar and labyrinth disorders1/57
Most frequent other events
Showing 10 of 20
Most frequent other events
EventIgPro10
HeadacheNervous system disorders38/57
PyrexiaGeneral disorders14/57
EpistaxisRespiratory, thoracic and mediastinal disorders11/57
ContusionInjury, poisoning and procedural complications10/57
PetechiaeSkin and subcutaneous tissue disorders7/57
NauseaGastrointestinal disorders6/57
Skin haemorrhageSkin and subcutaneous tissue disorders6/57
VomitingGastrointestinal disorders6/57
AnaemiaBlood and lymphatic system disorders6/57
HyperthermiaGeneral disorders5/57

Baseline characteristics

Age Continuous
Age Continuous(years)IgPro10
Mean38 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)IgPro10
Female34
Male23
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)IgPro10
Caucasian57
Weight
Weight(kg)IgPro10
Mean74.0 ± 15.5
Body Mass Index
Body Mass Index(kg/m^2)IgPro10
Mean25.69 ± 4.56
08

Study locations

17 sites
  • Study Site
    Berlin, Germany
  • Study Site
    Rome, Italy
  • Study Site
    Bialystok, Poland
  • Study Site
    Gdansk, Poland
  • Study Site
    Lodz, Poland
  • Study Site
    Poznan, Poland
  • Study Site
    Warsaw, Poland
  • Study Site
    Wroclaw, Poland
  • Study Site
    Moscow, Russian Federation
  • Study Site (19)
    St. Petersburg, Russian Federation
  • Study Site (20)
    St. Petersburg, Russian Federation
  • Study Site (21)
    St. Petersburg, Russian Federation
  • Study Site
    Dnipropetrovsk, Ukraine
  • Study Site (02)
    Kyiv, Ukraine
  • Study Site (03)
    Kyiv, Ukraine
  • Study Site
    Lviv, Ukraine
  • Study Site
    Taunton, United Kingdom
09

References and documents

Publications

  • Robak T, Salama A, Kovaleva L, Vyhovska Y, Davies SV, Mazzucconi MG, Zenker O, Kiessling P; International Privigen in ITP Study Group. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009 Aug;14(4):227-36. doi: 10.1179/102453309X439773. PubMed 19635187 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 14, 2005
Start
Dec 2004
CompletionActual
Feb 2006
Results first posted
Nov 23, 2011
Last update
Nov 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00168038
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Sep 14, 2005
Start date
Dec 2004
Completion
Feb 2006
Results posted
Nov 23, 2011
Last update
Nov 23, 2011

Study contacts

Othmar Zenker, MD
study director · CSL Behring
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion